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Abstract
Background
Neonates undergoing open-heart surgery are particularly at risk of postoperative bleeding
requiring blood transfusion. Aprotinin has attained high efficacy in reducing the requirement
for a blood transfusion following a cardiopulmonary bypass, but is seldom studied in the
neonatal age group. The aim of this study was to compare the efficacy and adverse
effects of aprotinin and tranexamic acid in neonates undergoing open-heart surgery at a
single centre.
Methods
Between October 2003 and March 2008, perioperative data of 552 consecutive neonatal
patients undergoing open-heart surgery in Children’s Hospital Boston were reviewed.
Among them, 177 did not receive antifibrinolytic therapy (Group A); 100 were treated with
tranexamic acid only (Group B); and 275 patients received aprotinin with or without tranexa-
mic acid (Group C). Except for antifibrinolytic therapy, the anaesthesiological and surgical
protocols remained identical. Postoperative complications and in-hospital mortality were
the primary study endpoints.
Results
Body weight and Risk Adjustment for Congenital Heart Surgery (RACHS-1) scores were
statistically comparable among the three groups. No statistically significant differences
were observed between the duration of hospitalization, chest tube drainage, reexploration
for bleeding, and kidney function impairment. In Group C, less blood was transfused within
24 hours than in GroupB. Operative mortality was similar among the three groups.
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Conclusion
No further risk and kidney injury were observed in the use of aprotinin in neonatal cardiac
surgery, aprotinin demonstrated a reduced requirement for blood transfusion compared
with tranexamic acid. Our data provide reasonable evidence that aprotinin and tranexamic
acid are safe and efficacious as antifibrinolytic modalities in neonatal patients undergoing
cardiac surgery.
Introduction
Cardiopulmonary bypass (CPB) and cardiovascular surgery activate coagulation, inflamma-
tion, and fibrinolysis, which often exert potentially deleterious effects on patient outcome, par-
ticularly if CPB is prolonged [1, 2]. The use of CPB to repair congenital cardiac defects among
neonates often subjects these young patients to wide ranges of physiologic derangement be-
cause of immature tissue and organ function in the first month of life. Neonates often experi-
ence more pronounced deleterious effects than those seen in large paediatric or adult patients,
partially because of the substantial disparity in CPB circuit size [3]. Although haemodilution
can produce impaired haemostasis related to both qualitative and quantitative abnormalities in
coagulation factors, leading to fibrinolysis [2–6], antifibrinolytics can be helpful in reducing
loss and transfusion requirements [7, 8].
Aprotinin (Trasylol; Bayer Pharmaceuticals Corporation, West Haven, CT, USA) is a non-
specific serine protease inhibitor that was first used as an antiinflammatory agent in the treat-
ment of acute pancreatitis in the 1960s. The beneficial effects of aprotinin in open-heart
surgery reportedly work by inhibiting kallikrein and plasmin, with decreased haemostatic acti-
vation, inhibition of fibrinolysis, and preservation of platelet function [9]. In a randomized
controlled trial published in 1987, aprotinin was found to reduce blood loss and the need of
transfusion in re-do open heart surgery [10]. In the following days, several randomized, pro-
spective, placebo-controlled, carefully performed trials on aprotinin use have indicated a re-
duced blood transfusion requirement in adult cardiac surgery [11]. By 1993, the Food and
Durg Administration (FDA) approved the use of aprotinin in coronary artery bypass grafting
for reducing blood loss [12]. Additionally, aprotinin has also reportedly decreased the inflam-
matory response to CPB, verified by reduced levels of proinflammatory cytokines in aprotinin-
treated patients [13, 14]. In 2008, the results of the Blood Conservation Using Antifibrinolytics
in a Randomized Trial (BART) were published [15]. BART was a multicentre, blinded, ran-
domized trial of 2331 high-risk cardiac surgery patients comparing aprotinin with a pair of ly-
sine analog drugs (tranexamic acid and epsilon-aminocaproic acid) owing to concerns of an
increased risk of deaths related to aprotinin. From the BART and other observation studies
[16–18], aprotinin has been associated with greater risk to benefit ratio among adult popula-
tions and the safety concern of aprotinin increased [19]. Consequently, aprotonin was with-
drawn and has been clinically unavailable in the United States since 2007. However, because of
the biological and procedural differences between surgery for congenital and acquired cardiac
disease, the paediatric experience remains relevant. Aprotinin reportedly decreased the use of
blood products and operative time in congenital heart surgery [20]. Additional benefits in con-
genital heart surgery include improved pulmonary function, particularly in patients undergo-
ing surgical palliation for single ventricle anatomy [21]. However, data regarding the safety and
efficacy of aprotinin in neonatal patients are limited.
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Tranexamic acid, a lysine analogue, is widely used to reduce blood loss; however, the blood-
sparing effect is often considered to be inferior to that of aprotinin [22]. Additionally, the safety
of aprotinin has been more extensively studied than that of tranexamic acid. A previous study
on paediatric cardiac surgery demonstrated increased susceptibility to seizure after tranexamic
acid treatment [23].
The purpose of this study was to determine the safety and efficacy of aprotinin and tranexa-
mic acid in neonatal patients undergoing CPB.
Patients and Methods
The Institutional Review Board of Children’s Hospital Boston, Boston, Massachusetts, United
States approved this retrospective, nonrandomised cohort study, and the approval included a
waiver of informed consent. Data were collected from a retrospective review of prospectively
collected data. From October 2003 to March 2008, 552 neonatal patients undergoing 565 cardi-
ac surgical procedures were enrolled in this study. Neonates were divided into three groups:
Group A: no antifibrinolytic group (n = 177); Group B: tranexamic acid group (n = 100); and
Group C: aprotinin or both aprotinin and tranexamic acid (n = 275). Demographic data were
recorded, including gender, weight and age at surgery, and prematurity. Intraoperative infor-
mation included deep hypothermic circulatory arrest, aortic cross-clamp time, CPB time, use
of Risk Adjustment for Congenital Heart Surgery (RACHS-1) scores to assess the complexity
of the procedures performed, and duration of hospitalization in days (ICU and ward). Renal
function was assessed by measuring pre- and postoperative serum creatinine (Cr). Require-
ments for extracorporeal membrane oxygenation (ECMO), reoperation for bleeding, blood
transfusion within 24 hours and in-hospital death were recorded and analysed.
The protocol consisted of administering a bolus of 100 mg/kg of tranexamic acid to the pa-
tient after induction of anaesthesia, followed by an infusion of 10 mg/kg/h until the end of the
operation, and 100 mg/kg was added to prime the CPB equipment. In the aprotinin group, a
bolus of 30,000 KIU/kg of aprotinin was administered to patients after the induction of anaes-
thesia, followed by an infusion of 10,000 KIU/kg/h until the end of the operation, and 30,000
KIU/kg was also added to the CPB prime.
In all other aspects, the surgical and anaesthesiological protocols remained unchanged. The
requirement of a transfusion was considered when the haemoglobin level was< 14 g/dL in cya-
notic patients, and< 10 g/dL in noncyanotic patients, or if a patient exhibited clinical signs in-
dicating the requirement for a higher oxygen carrying capacity. Reexploration for mediastinal
bleeding was based on clinical signs, including excessive chest-tube output. We did not have a
set criteria for exploration regarding chest-tube blood output.
Chart reviews consisted of preoperative, intraoperative and postoperative data collection.
Preoperative data included patient demographics: age, gender, weight, prematurity (defined
as< 36 wk gestation), and presence of a major noncardiac structural anomaly. Cardiac diagno-
sis and surgical procedure were recorded. All neonates were assigned a RACHS-1 score [24].
Neonates with a combination of cardiac surgical procedures were assigned the RACHS-1 score
of the highest risk procedure and the combination of procedures was treated as an independent
variable. Preoperative baseline creatinine (Cr) was also recorded. Intraoperative data included
the use of aprotinin or tranexamic acid, CPB time, aortic cross-clamp time, and deep hypother-
mic circulatory arrest time. Postoperative data were used to assess specific outcomes. Postoper-
ative Cr levels were recorded at 24 hours. Biochemical acute kidney failure was defined as an
increase in serum creatinine levels to double or more than the preoperative level. We also re-
corded the time to tracheal extubation and the duration of the intensive care unit stay, the du-
ration of chest-tube drainage, the use of ECMO and mortality before hospital discharge.
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The data included in our manuscript represents an entirely clinical data base obtained from
the department of surgery databases, without the reliance of administrative databases, and in-
cluded discrete information not available in previous publications.
Data analysis
The three groups of patients were compared using the preoperative, intraoperative, postopera-
tive complications results. Collected data were summarized descriptively and compared be-
tween each two of the three groups. The Shapiro-Wilk test was used to assess the normality
distribution assumption. Data were described using means and standard deviation, and com-
parisons were performed using an analysis of variance and a posthoc test if appropriate. Non-
normally distributed data were compared using the Kruskal-Wallis equality-of-populations
rank test and a posthoc test for multiple comparisons, as described in Siegel and Castellan [25].
Categorical data were analysed using Fisher’s exact test. Outcome data was presented using
Kaplan-Meier survival curves with a comparison between types of antifibrinolytic therapy by
using a log-rank test. A multivariable logistic regression model was used to evaluate the associ-
ation between antifibrinolytic therapy and death adjusted for a previously described set of co-
variates. The goodness of fit was evaluated using the Hosmer-Lemeshow chi-square. All
statistical analysis was performed using the STATA/IC 10.1 (STATA Corp, College Station,
TX, USA) software and statistical significance was assessed at the .05 level.
Results
Male patients predominated in all three groups. The demographic and intraoperative data
are listed in Table 1. Weight and the percentage of prematurity were comparable across the
three groups and no significant difference was observed in the RACHS scores. The K-W test in-
dicated that the median deep hypothermic circulatory arrest (DHCA) time in Group C was sig-
nificantly lower than that in Groups A and B (P = .00010). The median CPB time differed
significantly among the groups (P = .00275): between the control and tranexamic acid groups
(P = .005419), and the control and aprotinin groups (P = .00063). The total blood transfusion
within 24 hours after surgery (excluding reoperation for bleeding) varied among all three
groups (P = .0011) (Table 2). Chi-square analysis revealed no statistical differences in the
Table 1. Preoperative and intraoperative characteristics.
Characteristic Group ANo
antiﬁbrinolytic(n = 184)
Group B Tranexamic acid
only(n = 104)
Group C Aprotinin and both aprotinin
and tranexamic acid(n = 276)
p-Value
Patients, n 177 100 275
Male gender, n(%) 105 (59.3) 56 (56.0) 155 (58.4) 0.87
Age at surgery median (IQR) days 6 (4–12) 6 (4–12) 5 (4–8) 0.0036
Weight, mean (SD) Kg 3.06 (0.61) 3.26 (0.56) 3.10 (0.66) 0.0520
Prematurity, n 3 0 10 0.138
RACHS-1 score, median (IQR) 3 (3–6) 3 (3–4) 4 (3–6) 0.2850
Deep hypothermic circulatory
arrest, median (IQR) min
32 (13–48) 31.5 (12.5–49) 17 (9–27) 0.0001
CPB time, median (IQR) min 128 (100–158) 142 (116–166) 138 (120–163) 0.0027
Aortic cross-clamp time, median
(IQR) min
65 (48–94) 78 (54–99) 71 (57–86) 0.0971
CPB: Cardiopulmonary bypass; IQR: Interquartile range
doi:10.1371/journal.pone.0126514.t001
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incidence of acute kidney injury among the three groups (P = .655), and the odds ratio for
death was similar (Table 3). The estimated survival functions for death and being reoperation-
free between the antifibrinolytic therapy groups were also similar (P = .2841 and .2897) (Fig 1).
Discussion
Congenital heart disease (CHD) has long been associated with coagulation abnormalities [26],
including platelet abnormalities [27] and fibrinolysis [28]. To overcome these adverse effects,
attempts have been made to modify these effects with both lysine analogue, antifibrinolytics,
and aprotinin. Aprotinin is a broad-spectrum serine protease inhibitor that protects platelets
by preventing their activation on CPB [29]. Previous reports focusing on aprotinin in patients
Table 2. Postoperative characteristics andmorbidity/mortality.
Characteristic Group ANo
antiﬁbrinolytic(n = 184)
Group B Tranexamic acid
only(n = 104)
Group C Aprotinin and both aprotinin and
tranexamic acid(n = 276)
p-Value
Total blood transfusion within 24
h, mean (STD) ml
39.8±47.0 47.7±51.0 32.0±40.0 0.011
ICU LOS, median (IQR) days 11 (7–19) 13 (9–20) 11 (9–18) 0.6395
Hospital LOS (days), median
(range)
16 (12–28) 19(12–34) 16(16–26) 0.2575
Chest tube drainage (days),
median (range)
4 (1–63) 4(1–63) 4(1–44) 0.5324
Acute kidney injury, n (%) 16 (8.7%) 10 (9.6%) 31 (11.2%) 0.655
Reopen chest, n (%) 9 (4.9%) 7 (6.7%) 10 (3.6%) 0.4270
ECMO support, n (%) 2 (1.1%) 0 (0%) 7 (2.5) 0.1690
Hospital mortality, n (%) 29 (15.8%) 8 (7.7%) 28 (10.1%) 0.072
doi:10.1371/journal.pone.0126514.t002
Table 3. Adjusted effect of antifibrinolytic therapy on odds ratio for death.
Risk factor OR P value [95%CI for OR]
None 1.00*
Transexamic Ac 0.27 0.092 0.06–1.23
Aprotinin 0.31 0.357 0.02–3.62
Gender(female ref) 1.27 0.720 0.33–4.79
Age at surgery 1.05 0.240 0.96–1.16
Days in Hospital 0.77 0.001 0.67–0.89
Days in CICU 1.35 <0.001 1.16–1.57
Cross-clamp Ao 0.96 0.039 0.93–0.99
CPB temp 1.21 0.012 1.04–1.41
CPB time 1.02 0.020 1.00–1.05
RACHS-1 level 1–2 1.00*
RACHS-1 level 3 1.28 0.816 0.15–10.4
RACHS-1 level 4 0.73 0.831 0.04–12.6
RACHS-1 level 6 7.31 0.084 0.76–69.9
Creatinine pre-post 3.74 0.385 0.19–73.9
Transfusion < 24h 0.98 0.200 0.97–1.00
*Reference group of the following OR.
Hosmer-Lemeshow chi2 (8) = 3.73Prob > chi2 = 0.8805
doi:10.1371/journal.pone.0126514.t003
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with various congenital heart diseases who underwent cardiac operation have consistently re-
vealed a decrease in postoperative blood loss [30]. However, there is no definite conclusion re-
garding the efficacy of antifibrinolytic therapy in neonatal patients undergoing cardiac
operation. Because analyses of the effects on paediatric cardiac operations have been hampered
by various confounding factors, undefined transfusion triggers, various dosing protocols and
institutional preference, information regarding the efficacy of aprotinin in neonates remains
limited and occasionally conflicting [31, 32]. In our study, using specified transfusion triggers,
blood transfusion within 24 hours was significantly less common among those who received
aprotinin (32.0 ± 40.0 mL) compared with the other two groups (P = .011) (39.8 ± 47.0 mL in
Group A and 47.7 ± 51.0 mL in Group B).
Numerous studies have reported findings demonstrating increased mortality and renal fail-
ure in cardiac surgery patients [15,19]. Aprotinin was suspended at the FDAs request and re-
moved from the market in 2007. Some publications suggested that the withdrawal of aprotinin
has been detrimental to patients undergoing cardiac surgery due to increased adverse outcomes
and use of blood products [33–35], but others found a relatively minimal influence in clinical
practice [36]. However, no randomized multicentre study has demonstrated any robust adverse
events in a paediatric group, particularly among neonates undergoing cardiac surgery [37–40].
Because of the concern that children undergoing congenital heart operations are more prone to
bleeding than adults are [41], tranexamic acid is considered the second most suitable alterna-
tive to antifibrinolytic therapy. Schindler et al. reported that aprotinin can be replaced with
Fig 1. Kaplan-Mier survival curve.
doi:10.1371/journal.pone.0126514.g001
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tranexamic acid because of the equal blood sparing effects, but they also indicated that the evi-
dence accumulated at present remains insufficient to clearly estimate the benefits and risks as-
sociated with the use of tranexamic acid in congenital heart surgery [42].
In addition to its antifibrinolytic property, aprotinin might exert an attenuating effect on
the inflammatory response to CPB. This effect can be particularly beneficial to neonates who
often exhibit a marked inflammatory reaction and capillary leak syndrome during CPB [43]. In
a study conducted by Hsia et al. with the aim of exploring the effects of aprotinin or tranexamic
acid on proteolytic and cytokine profiles in infants after cardiac surgery, the expression of
proinflammatory cytokines and associated matrix metaloproteinases was reduced in an aproti-
nin group compared with a tranexamic acid group [44]. Two currently published reports also
demonstrated that aprotinin attenuates postoperative expression of pro-inflammatory factors
and inflammatory gene expression whereas tranexamic acid does not [45,46]. Theses results
were consistent with prior studies of cardiac surgery patients [13,14,47–49].Because of the ret-
rospective form of the present study, we lacked data for specific biomarkers of inflammation.
However, from the clinical parameters of postoperative recovery outocmes such as chest-tube
drainage, duration of stay in the intensive care unit, duration of hospitalization and in-hospital
mortality indicated no statistically significant differences among the three groups, suggesting
that the potential antiinflammatory effect of aprotinin was clinically negligible.
One of the major side effects of aprotinin therapy in neonatal patients is renal injury. Renal
injury has been extensively studied in aprotinin, because it is appropriated by the brush border
of the renal tubules after filtration that has caused concerns regarding the potential for renal
toxicity [50]. The possible effects of aprotinin on renal function have been both experimentally
and clinically described (e.g. decreased kinin synthesis, diminished renal blood flow and glo-
merular filtration rate, and reversible tubular overload) [51]. In adult cardiac surgery patients,
Wagener et al. observed that the use of aprotinin was associated with both an increased risk of
acute renal injury and an increase of urinary neutrophil gelatinase-associated lipocalin, which
is a sensitive marker for renal injury [52]. The adverse effects of aprotinin varying with the age
of patients remains unsubstantiated. In a cohort study presented by Backer et al. that examined
aprotinin safety in congenital heart operations, no association was observed between aprotinin
use and acute renal failure, dialysis requirement, neurologic complication or mortality [53].
Another large-scale study involving 35 children’s hospitals also concluded that the use of apro-
tinin in congenital heart operations is safe without increased mortality or dialysis [54]. Howev-
er, in a recently published study by Leyvi et al. [55], higher odds of acute renal injury were
observed, compared with ε-aminocaproic acid, suggesting that the established concerns for
adults with adverse kidney effects treated using aprotinin are also applicable to paediatric pa-
tients. In our study, postoperative creatinine levels after 24 hours were significantly higher than
preoperative creatinine levels in all three groups. However, no evidence was found for the pro-
gression to renal failure or dialysis following administration of either aprotinin or
tranexamic acid.
From the accumulated evidence, aprotinin effectively reduces blood loss and the need of
blood transfusion associated with heart surgery and currently in Canada and the EU, Health
Canada, and the EMA believe the benefits of aprotinin outweight its risks in isolated CABG
surgery [56,57]. Wilder et al also demonstrated that aprotinin had significantly lower intrao-
perative transfusion requirements, surgical reexploration, renal injury and shorter surgical
times in neonate heart operations [58]. These studies clearly illustrate the need for further
large-scale randomized, well-designed with adequately grouped clinical trial to investigate the
safety and efficacy of aprotinin in cardiac surgery.
The present report demonstrates single center data analysis that is unique and important
with clinical significance. The limitations of this study include retrospective design, omitted
Antifibrinolytics in Neonatal Cardiac Surgery
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variable bias in the database, lack of strictly defined transfusion triggers, lack of some direct
measures of inflammation markers, possibility of type 2 error which is related to the power.
Additionally, some factors including median cardiopulmonary bypass time and deep hypother-
mic circulatory arrest time may influence coagulation and fibrinolysis and thus confound the
data interpretation.
Conclusions
In conclusion, our study demonstrated that neonates who received aprotinin benefited from
the blood-sparing effects without increasing the risk of acute renal injury and other adverse
clinical outcomes. The data provide reasonable evidence that aprotinin and tranexamic
acid are safe and efficacious as antifibrinolytic modalities in neonatal patients undergoing
cardiac surgery.
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